---
title: "FDA Rejects Capricor’s Cell Therapy deramiocel for Duchenne Muscular Dystrophy"
id: "stat-news-0-stat-fda-rejects-capricor-therapeutics-duchenne-therapy-a-decision-that-was-a"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-rejects-capricor-therapeutics-duchenne-therapy-a-decision-that-was-a"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/?utm_campaign=rss"
published_at: "2026-11-20T23:43:53.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA Rejects Capricor’s Cell Therapy deramiocel for Duchenne Muscular Dystrophy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-rejects-capricor-therapeutics-duchenne-therapy-a-decision-that-was-a
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/?utm_campaign=rss)
- **Published At:** 2026-11-20T23:43:53.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The Food and Drug Administration issued a rejection for Capricor Therapeutics’ cell therapy **deramiocel** for **Duchenne muscular dystrophy** on Nov. 20, 2026, the source reported. - The therapy was intended for teenagers and young men with Duchenne who had lost the ability to walk; that patient group has limited treatment options, the article noted. - Capricor ran two randomized clinical trials of deramiocel. Both trials failed to demonstrate that the therapy could prevent heart failure or preserve arm muscle function, investigators reported. - The report said the negative results made the FDA decision straightforward from an efficacy perspective; nevertheless, Duchenne regulatory decisions are often complex because the disease is progressive and rare. - The STAT article is a subscriber-only (STAT+) story; the public summary in the source emphasized efficacy failure rather than safety or other regulatory considerations. - The source did not report detailed trial methodology, primary endpoints, sample sizes, statistical results, dosing, safety data, or Capricor’s immediate corporate response and planned next regulatory steps. - The article did not specify what regulatory path Capricor might pursue next, whether an appeal or additional data submission is planned, and it did not provide FDA briefing documents or advisory committee materials.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/?utm_campaign=rss) [research](https://www.statnews.com/topic/research/) [FDA](https://www.statnews.com/topic/fda/) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT@JPM27](https://www.statnews.com/jpm-conference-stat-events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [STAT Plus](https://www.statnews.com/stat-plus/)Opinion[Adam’s Take](https://www.statnews.com/category/adams-take/) # FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming ## A public pressure campaign couldn’t alter the hard reality: The drug didn’t work * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/09/GettyImages-1227710420-1-645x645.jpg) Sarah Silbiger/Getty Images ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Nov. 20, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of [Adam’s Biotech Scorecard](https://www.statnews.com/category/adams-biotech-scorecard/), a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics. The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make. The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today. Deramiocel didn’t help them either. Capricor [conducted two randomized clinical trials](https://www.statnews.com/2026/07/27/fda-efficacy-doubts-capricor-therapeutics-duchenne-muscular-dystrophy/). Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms. Advertisement But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [rare diseases](https://www.statnews.com/topic/rare-diseases/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AP26268824755916-80x80.jpg) [ICE detention of Princeton scientist rattles academia](https://www.statnews.com/2026/11/20/princeton-researcher-eva-yi-xie-ice-detention-rattles-interational-scholars/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/03/GettyImages-2187619311-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [UnitedHealth sues to reverse downgraded Medicare Advantage quality scores](https://www.statnews.com/2026/11/20/unitedhealth-cms-medicare-advantage-lawsuit-star-rating/) 3. ![](https://www.statnews.com/wp-content/uploads/2025/09/TheWorkup_Illustration_MollyFerguson_093025-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins](https://www.statnews.com/2026/11/19/deprescribing-statins-study-stream-trial-aha-questions/) 4. ![](https://www.statnews.com/wp-content/uploads/2021/03/Pharmalot_ComingGoing_STILL-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Up and down the ladder: The latest comings and goings](https://www.statnews.com/pharmalot/2026/11/20/up-and-down-the-ladder-latest-comings-and-goings-jobs-2/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/image-9-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Epic Systems defends competitive practices, promises to let AI access its records](https://www.statnews.com/2026/11/18/epic-defends-competitive-practices-promises-ai-access-to-records/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/09/TheWorkup_Illustration_MollyFerguson_093025-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins](https://www.statnews.com/2026/11/19/deprescribing-statins-study-stream-trial-aha-questions/) 2. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 3. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_587333568_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In a win for MAHA, FDA creates new regulatory category for the supplement NAC](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/LabDish_Frame_rfkjr-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [RFK Jr. has got to go](https://www.statnews.com/2026/11/18/kennedy-impeachment-paul-knoepfler-says-time-is-now/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 19, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment ](https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Take Adam's Take November 17, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial ](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to know about Biogen’s big lupus study readout ](https://www.statnews.com/2026/11/12/biogen-lupus-litifilimab-what-to-know/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem ](https://www.statnews.com/2026/11/12/alnylam-amvuttra-heart-drug-growth/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 5, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: A closer look at ProMis Neurosciences and its Alzheimer’s drug ](https://www.statnews.com/2026/11/05/promis-neurosciences-alzheimers-disease-acumen-vertex-kidney-drug/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Epic Systems defends competitive practices, promises to let AI acces
## Related Clinical Research

- [Exercise Prescriptions for Concussion Recovery: An Urgent Call to Action](https://medichelpline.com/clinical-feed/stat-news-2-opinion-more-doctors-should-prescribe-exercise-after-a-concussion.md)
- [Capsida follow-up: investigators report progress after death in gene therapy trial](https://medichelpline.com/clinical-feed/stat-news-0-stat-after-death-in-gene-therapy-trial-for-a-brain-disease-progress-is-reported.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)
- [Which Exercises Best Target Blood Pressure, Blood Sugar, and Cholesterol in Metabolic Syndrome?](https://medichelpline.com/clinical-feed/medical-news-today-0-how-do-different-exercises-target-blood-pressure-blood-sugar-and-cholesterol.md)
- [Planetary Health Diet Linked to Lower Cardiovascular Risk in Postmenopausal Women](https://medichelpline.com/clinical-feed/medical-news-today-0-plant-based-planetary-health-diet-could-help-protect-heart-health.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.